Antihistamine use in children

Archives of Disease in Childhood: Education and Practice Edition

Volumn 100, Issue 3, 2015, Pages 122-131

  Fitzsimons, Roisin ^a,b   Van Der Poel, Lauri Ann ^a   Thornhill, William ^a   Du Toit, George ^a,b   Shah, Neil ^c,d   Brough, Helen A ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIVASTINE; ADRENALIN; ANTIHISTAMINIC AGENT; AZELASTINE; CETIRIZINE; CHLORPHENIRAMINE; DESLORATADINE; FEXOFENADINE; HISTAMINE RECEPTOR; HYDROXYZINE; IMMUNOGLOBULIN E; KETOTIFEN; LEVOCETIRIZINE; LORATADINE; OLOPATADINE; PROMETHAZINE;

ALLERGIC DISEASE; ALLERGIC REACTION; ALLERGIC RHINITIS; ALLERGY; ANAPHYLAXIS; ASTHMA; ATOPIC DERMATITIS; BIOTRANSFORMATION; CHILD; CHRONIC COUGH; CONJUNCTIVITIS; DRUG ABSORPTION; DRUG MECHANISM; DRUG SAFETY; EMERGENCY TREATMENT; HUMAN; LICENSING; PRIORITY JOURNAL; PROTEIN INTAKE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; URTICARIA; CLASSIFICATION; CONJUNCTIVITIS, ALLERGIC; DERMATITIS, ATOPIC; HYPERSENSITIVITY; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

CHILD; CONJUNCTIVITIS, ALLERGIC; DERMATITIS, ATOPIC; HISTAMINE ANTAGONISTS; HUMANS; HYPERSENSITIVITY; RECEPTORS, HISTAMINE; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; URTICARIA;

EID: 84929618201     PISSN: 17430585     EISSN: 17430593     Source Type: Journal    
DOI: 10.1136/archdischild-2013-304446     Document Type: Review

References (51)

1. Helms PJ, Ekins DS, Taylor MW, et al. Utility of routinely acquired primary care data for paediatric disease epidemiology and pharmacoepidemiology. Br J Clin Pharmacol 2005;59:684-90.
2. Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. [Erratum appears in Lancet 2007;370(9593):1128].
3. Lancet 2006;368:733-43.
4. Gupta R, Sheikh A, Strachan DP, et al. Time trends in allergic disorders in the UK. Thorax 2007;62:91-6.
5. Simons FE. Advances in H1-antihistamines. [Review] [120 refs]. N Engl J Med 2004;351:2203-17.
6. Simons FE, Simons KJ. H1 antihistamines: current status and future directions. World Allergy Organ J 2008;1:145-55.
7. Simons FE. Comparative pharmacology of H1 antihistamines: clinical relevance. [Review] [28 refs]. Am J Med 2002;113(Suppl):46S.
8. Yu F, Bonaventure P, Thurmond RL. The future antihistamines: histamine H3 and H4 receptor ligands. [Review]. Adv Exp Med Biol 2010;709:125-40.
9. Church MK, Church DS. Pharmacology of antihistamines. Indian J Dermatology 2013;58:219-24.
10. Simons FE, Luciuk GH, Simons KJ. Pharmacokinetics and efficacy of chlorpheniramine in children. J Allergy Clin Immunol 1982;69:376-81.
11. Royal Pharmaceutical Society of Great Britain, RCPCH Publications Ltd, BMJ. British national formulary for children. BMJ Publishing Group Ltd, 2014.
12. Shimamura T, Shiroishi M, Weyand S, et al. Structure of the human histamine H1 receptor complex with doxepin. Nature 2011;475:65-70.
13. Holgate ST, Canonica GW, Simons FE, et al. Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. [Review] [116 refs]. Clin Exp Allergy 2003;33:1305-24.
14. de Blic J, Wahn U, Billard E, et al. Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Pediatr Allergy Immunol 2005;16:267-75.
15. Watson WT, Simons KJ, Chen XY, et al. Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. J Allergy Clin Immunol 1989;84(4: Pt 1):457-64.
16. Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002;71:11-20.
17. Diepgen TL. Early Treatment of the Atopic Child Study Group. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol 2002;13:278-86.
18. Simons FE. Early Prevention of Asthma in Atopic Children (EPAAC) Study Group. Safety of levocetirizine treatment in young atopic children: An 18-month study. Pediatr Allergy Immunol 2007;18:535-42.
19. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010;126:466-76.
20. Powell RJ, Du Toit GL, Siddique N, et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy 2007;37:631-50.
21. Traidl-Hoffmann C, Munster I, Ring J, et al. Impact of desloratadine and loratadine on the crosstalk between human keratinocytes and leukocytes: Implications for anti-inflammatory activity of antihistamines. Int Arch Allergy Immunol 2006;140:315-20.
22. Canonica GW, Blaiss M. Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: a review of the evidence. World Allergy Organ J 2011;4:47-53.
23. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. [Review] [97 refs]. N Engl J Med 2003;349:1157-67.
24. Simons FER. H1-antihistamines in children. Histamine and H1-antihistamines in allergic disease. 2nd edn. New York: Marcel Dekker, Inc, 2002.
25. Soar J, Pumphrey R, Cant A, et al. Emergency treatment of anaphylactic reactions-guidelines for healthcare providers. Resuscitation 2008;77:157-69.
26. Church MK, Maurer M, Simons FE, et al. Risk of first-generation H (1)-antihistamines: a GA (2) LEN position paper. [Review] [77 refs]. Allergy 2010;65:459-66.
27. Sheikh A, Ten Broek V, Brown SG, et al. H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review. [Review] [40 refs]. Allergy 2007;62:830-7.
28. Walker S, Khan-Wasti S, Fletcher M, et al. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol 2007;120:381-7.
29. Del Cuvillo A, Sastre J, Montoro J, et al. Use of antihistamines in pediatrics. [Review] [106 refs]. J Investig Allergol Clin Immunol 2007;17(Suppl):40.
30. Scadding GK, Durham SR, Mirakian R, et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy 2008;38:19-42.
31. Ratner PH, Hampel F, Van BJ, et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2008;100:74-81.
32. Guest JF, Clegg JP, Smith AF. Health economic impact of olopatadine compared to branded and generic sodium cromoglycate in the treatment of seasonal allergic conjunctivitis in the UK. Curr Med Res Opin 2006;22:1777-85.
33. Thomas M, Kocevar VS, Zhang Q, et al. Asthma-related health care resource use among asthmatic children with and without concomitant allergic rhinitis. Pediatrics 2005;115:129-34.
34. Corren J, Manning BE, Thompson SF, et al. Rhinitis therapy and the prevention of hospital care for asthma: a case-control study. J Allergy Clin Immunol 2004;113:415-19.
35. Shields MD, Bush A, Everard ML, et al. British Thoracic Society Cough Guideline Group. BTS guidelines: recommendations for the assessment and management of cough in children. Thorax 2008;63(Suppl):iii15.
36. Chang AB, Peake J, McElrea MS. Anti-histamines for prolonged non-specific cough in children. [Review] [60 refs] [Update of Cochrane Database Syst Rev 2006;(3):CD005604; PMID: 16856107].
37. Cochrane Database Syst Rev 2008;(2):CD005604.
38. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA (2) LEN/EDF/WAO guideline: management of urticaria. [179 refs]. Allergy 2009;64:1427-43.
39. Handa S, Dogra S, Kumar B. Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria. J Dermatol Treat 2004;15:55-7.
40. Church MK, Maurer M. H (1)-antihistamines and urticaria: how can we predict the best drug for our patient?. [Review]. Clin Exp Allergy 2012;42:1423-9.
41. Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 2010;125:676-82.
42. Tsakok T, Du Toit G, Flohr C. Pediatric urticaria. Immunol Allergy Clin North Am 2014;34:117-39.
43. Meyer R, Scharz C, Shah N. A review on the diagnosis and management of food-induced gastrointestinal allergies. Curr Allergy Clin Immunol 2012;25:10-17.
44. Melamed I, Feanny SJ, Sherman PM, et al. Benefit of ketotifen in patients with eosinophilic gastroenteritis. Am J Med 1991;90:310-14.
45. Molkhou P, Dupont C. Ketotifen in prevention and therapy of food allergy. Ann Allergy 1987;59(5: Pt2):187-93.
46. Dominguez-Ortega G, Meyer R, Dziubak R, et al. Gastrointestinal food allergy assessment by a symptom questionnaire [abstract]. Allergy 2013;68(Suppl.97):333.
47. Untersmayr E, Jensen-Jarolim E. The role of protein digestibility and antacids on food allergy outcomes. [Review] [148 refs]. J Allergy Clin Immunol 2008;121:1301-8.
48. National Institute for Health and Clinical Excellence. Atopic eczema in children: Management of atopic eczema in children from birth up to the age of 12 years. 2007. http://www.nice.org.uk/guidance/CG57
49. Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. [Review] [200 refs]. Allergy 2006;61:969-87.
50. Chemists and Druggists. Guide to OTC Medicines and Diagnostics. 2014.
51. Royal Pharmaceutical Society. Legal classification of medicines. http://wwwrpharms.com/ (Accessed May 2014).